Search
Search
About
Log in
Join
Experiences with
Triple bromide
Posts
Communities
5,301 public posts
Filter results
Bronchiectasis clinical trials
Hi All, Not sure if the following might be of interest, perhaps some of you are already involved but you never know. https://clinicaltrials.gov/ct2/show/NCT04594369 If anyone has any feedback, would be pleased to hear. Have a good day, Chris.
Hi All, Not sure if the following might be of interest, perhaps some of you are already involved but you never know. https://clinicaltrials.gov/ct2/show/NCT04594369 If anyone has any feedback, would be pleased to hear. Have a good day, Chris.
LissacFrance
in
Lung Conditions Community Forum
2 years ago
Micro-Mets Next Steps
Beloved, well-read, much-experienced cancer colleagues, My PSA has gone up quite slowly since being OFF all ADT since 2015-16 clinical trial on Lupron and Apaludimide (I had heart attack and a TIA then- my oncologist has not urged me to go back on ADT since). My PSA is now just under 2.7 but was 1.4
Beloved, well-read, much-experienced cancer colleagues, My PSA has gone up quite slowly since being OFF all ADT since 2015-16 clinical trial on Lupron and Apaludimide (I had heart attack and a TIA then- my oncologist has not urged me to go back on ADT since). My PSA is now just under 2.7 but was 1.4
SeattleDan
in
Advanced Prostate Cancer
2 years ago
Latest from BATman Denmeade
New paper [1].
Bipolar androgen therapy (BAT): A patient's guide
[i]Bipolar androgen therapy (BAT) is a new treatment concept for men whose prostate cancer has become resistant to standard hormone-blocking therapy. Over the past decade, we have performed a series of clinical studies testing BAT
New paper [1].
Bipolar androgen therapy (BAT): A patient's guide
[i]Bipolar androgen therapy (BAT) is a new treatment concept for men whose prostate cancer has become resistant to standard hormone-blocking therapy. Over the past decade, we have performed a series of clinical studies testing BAT
pjoshea13
in
Advanced Prostate Cancer
2 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Effect of Melatonin Administration on Mitochondrial Activity and Oxidative Stress Markers in Patients with Parkinson’s Disease 2021
The full report is available to read. Results are based on lab tests, but still very exciting. Interesting that they took 25 mg at noon and 25 mg 30 minutes before bedtime: Effect of Melatonin Administration on Mitochondrial Activity and Oxidative Stress Markers in Patients with Parkinson’s Disease https
The full report is available to read. Results are based on lab tests, but still very exciting. Interesting that they took 25 mg at noon and 25 mg 30 minutes before bedtime: Effect of Melatonin Administration on Mitochondrial Activity and Oxidative Stress Markers in Patients with Parkinson’s Disease https
Bolt_Upright
in
Cure Parkinson's
2 years ago
CD19 CAR-T cell therapy for B-ALL achieved remarkable efficacy with a complete remission of 70–90%
This looks interesting but way over my knowledge base. Perhaps some of you super brains can figure this out. In recent years, the increasing advancements and applications of cellular immunotherapy have enabled the use of chimeric antigen receptor (CAR) T cell therapy, and it has emerged as an efficacious
This looks interesting but way over my knowledge base. Perhaps some of you super brains can figure this out. In recent years, the increasing advancements and applications of cellular immunotherapy have enabled the use of chimeric antigen receptor (CAR) T cell therapy, and it has emerged as an efficacious
Scout4answers
in
Advanced Prostate Cancer
2 years ago
Evusheld shots - What now?
I just had the two Evusheld shots this week. I had CLL for several years and last November completed a 15 month clinical trial (041702) with Ibrutinib, Obinituzumab and Venetoclax. Happily, at the end I was declared uMRD. I have had 3 Pfizer shots and then a Moderna a month ago. None of these generated
I just had the two Evusheld shots this week. I had CLL for several years and last November completed a 15 month clinical trial (041702) with Ibrutinib, Obinituzumab and Venetoclax. Happily, at the end I was declared uMRD. I have had 3 Pfizer shots and then a Moderna a month ago. None of these generated
Iupiter
in
CLL Support
2 years ago
LU177 3rd dose
Hi! Well finaly my dad got in to the Lu177 clinical trials in Moscow. 1st round was 23 of Feb, then 2nd in 24 of March. Both time he got 9Gb of Lu 177. PSA before 1st injection was 112 and before 2nd 63. In this clinical trial they are using smal dosage 3,5 Gb but with short gap 2-4 weeks. But we decided
Hi! Well finaly my dad got in to the Lu177 clinical trials in Moscow. 1st round was 23 of Feb, then 2nd in 24 of March. Both time he got 9Gb of Lu 177. PSA before 1st injection was 112 and before 2nd 63. In this clinical trial they are using smal dosage 3,5 Gb but with short gap 2-4 weeks. But we decided
Zhyravlik
in
Advanced Prostate Cancer
2 years ago
1Trial of Bradykinesia Stem Cell Therapy Now Dosing Last Group
IMAC Holdings has started dosing the third and final group of participants in a Phase 1 clinical trial assessing the potential of its umbilical cord-derived stem cell therapy for treating bradykinesia, an early motor symptom of Parkinson’s disease characterized by slowness or difficulty in movement.
IMAC Holdings has started dosing the third and final group of participants in a Phase 1 clinical trial assessing the potential of its umbilical cord-derived stem cell therapy for treating bradykinesia, an early motor symptom of Parkinson’s disease characterized by slowness or difficulty in movement.
Farooqji
in
Cure Parkinson's
2 years ago
The coming rejuvenation biotechnology revolution for Parkinson's disease - Michael Rae and Dr. Robert Rodgers discuss Parkinson’s and aging
Hey Turnipbarrow , it is your fault I found this. Touches on Zombie neurons! The coming rejuvenation biotechnology revolution for Parkinson's disease - Michael Rae and Dr. Robert Rodgers discuss Parkinson’s and aging https://www.blogtalkradio.com/parkinsons-recovery/2022/01/09/the-coming-rejuvenation-biotechnology-revolution-for-parkinsons-disease
Hey Turnipbarrow , it is your fault I found this. Touches on Zombie neurons! The coming rejuvenation biotechnology revolution for Parkinson's disease - Michael Rae and Dr. Robert Rodgers discuss Parkinson’s and aging https://www.blogtalkradio.com/parkinsons-recovery/2022/01/09/the-coming-rejuvenation-biotechnology-revolution-for-parkinsons-disease
Bolt_Upright
in
Cure Parkinson's
2 years ago
Encouraging Stem Cell Trial Results
Top-line Parkinson's Disease Clinical Trial Results ISCO successfully completed the treatment phase of its dose escalating phase 1 clinical trial (ClinicalTrials.gov Identifier: NCT02452723) evaluating the safety, tolerability, and preliminary efficacy of its lead candidate, ISC-hpNSC® for the treatment
Top-line Parkinson's Disease Clinical Trial Results ISCO successfully completed the treatment phase of its dose escalating phase 1 clinical trial (ClinicalTrials.gov Identifier: NCT02452723) evaluating the safety, tolerability, and preliminary efficacy of its lead candidate, ISC-hpNSC® for the treatment
jimcaster
in
Cure Parkinson's
2 years ago
A randomized clinical trial of burst vs. spaced physical therapy for Parkinsons disease
https://www.prd-journal.com/article/S1353-8020(22)00054-2/fulltext
https://www.prd-journal.com/article/S1353-8020(22)00054-2/fulltext
Farooqji
in
Cure Parkinson's
3 years ago
Recording available - Dr. Jonathan Sackner-Bernstein: "What If I Discovered the Silver Bullet?"
Thank you to Dr. Jonathan Sackner-Bernstein for his excellent, thought-provoking presentation yesterday titled "What if I discovered the Silver Bullet?" Motivated by a friend’s suffering from Parkinson’s, Dr. Sackner-Bernstein focused on a gap in our understanding of the disease: no one had so far measured
Thank you to Dr. Jonathan Sackner-Bernstein for his excellent, thought-provoking presentation yesterday titled "What if I discovered the Silver Bullet?" Motivated by a friend’s suffering from Parkinson’s, Dr. Sackner-Bernstein focused on a gap in our understanding of the disease: no one had so far measured
Michel0220
in
Cure Parkinson's
3 years ago
Focus on thalassemia and polycythemia vera.
« Silence Therapeutics’ stuttering effort to generate clinical data on SLN124 in myelodysplastic syndrome (MDS) has conked out. Facing recruitment challenges, the RNAi specialist has decided to stop enrollment in the MDS arm of an early-phase clinical trial to focus on thalassemia and polycythemia vera
« Silence Therapeutics’ stuttering effort to generate clinical data on SLN124 in myelodysplastic syndrome (MDS) has conked out. Facing recruitment challenges, the RNAi specialist has decided to stop enrollment in the MDS arm of an early-phase clinical trial to focus on thalassemia and polycythemia vera
Manouche
in
MPN Voice
3 years ago
People of HU: Meet Hazel - Overcoming My Fear to Survive Kidney Cancer
March is kidney cancer awareness month. According to Cancer Research UK, Kidney cancer is the seventh most common cancer in the UK with 36 new cases being diagnosed every day. In this blog post, Hazel shares her story of being diagnosed with kidney cancer and overcoming her fear to proceed with the
March is kidney cancer awareness month. According to Cancer Research UK, Kidney cancer is the seventh most common cancer in the UK with 36 new cases being diagnosed every day. In this blog post, Hazel shares her story of being diagnosed with kidney cancer and overcoming her fear to proceed with the
SaskiaHU
HealthUnlocked
in
HealthUnlocked Blog
3 years ago
Decision time Lutetium or AM509
M1, five bone lesions, mCRPC with PSA now doubling each month (currently at 1.7), after failure of abiraterone. I've been offered a "slot" for two clinical trials: AMG509, a bi-specific T-cell engager, and a new version of Lutetium therapy, called Lu-DOTA-TLX590-CHO (which they say is novel, and seems
M1, five bone lesions, mCRPC with PSA now doubling each month (currently at 1.7), after failure of abiraterone. I've been offered a "slot" for two clinical trials: AMG509, a bi-specific T-cell engager, and a new version of Lutetium therapy, called Lu-DOTA-TLX590-CHO (which they say is novel, and seems
MarkEmrys
in
Advanced Prostate Cancer
3 years ago
Abiraterone and fatigue in 78 year old dad
Abiraterone and fatigue Hi my dad is 78 in April and lives in England. He had prostate surgery in 2019 but cancer had already spread. He's had chemo and ADT. His PSA went from 3.3 last Sept to 7.9 in November. A PSMA scan revealed he had Mets to Lymph nodes and some low-volume skeletal lesions in right
Abiraterone and fatigue Hi my dad is 78 in April and lives in England. He had prostate surgery in 2019 but cancer had already spread. He's had chemo and ADT. His PSA went from 3.3 last Sept to 7.9 in November. A PSMA scan revealed he had Mets to Lymph nodes and some low-volume skeletal lesions in right
Lemonpower
in
Advanced Prostate Cancer
3 years ago
Third Jevtana/Carboplatin treatment completed. Total of 10 chemo treatments are now completed overall. Hoping for better results.
PSA increase as seen above. My oncologist's response was "This may be the roller coaster that your PSA is following We will continue to monitor the levels and symptoms" Seems to me the best part of the old wooden coaster was cresting the top of the climb and plunging to the bottom. Hopefully, my next
PSA increase as seen above. My oncologist's response was "This may be the roller coaster that your PSA is following We will continue to monitor the levels and symptoms" Seems to me the best part of the old wooden coaster was cresting the top of the climb and plunging to the bottom. Hopefully, my next
Mount_Rainier
in
Advanced Prostate Cancer
3 years ago
Parkinson’s Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy? 2021
There is a LOT to read in this article. And it is very detailed and I did not understand most of it. But if you browse through it, things will pop out. Tidbits. Clues. Parkinson’s Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy? https://www.frontiersin.org/articles/10.3389
There is a LOT to read in this article. And it is very detailed and I did not understand most of it. But if you browse through it, things will pop out. Tidbits. Clues. Parkinson’s Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy? https://www.frontiersin.org/articles/10.3389
Bolt_Upright
in
Cure Parkinson's
3 years ago
COVID and stage 4 HRPC warning!!
While waiting to join a clinical trial my bf got I'll. He stopped eating, had nausea and vomiting , chills , cough and weakness. Concerned about possible pneumonia , I took him to the ER. I explained all the symptoms and informed them about his vaccines. As soon as a hospitalist saw him and diagnosed
While waiting to join a clinical trial my bf got I'll. He stopped eating, had nausea and vomiting , chills , cough and weakness. Concerned about possible pneumonia , I took him to the ER. I explained all the symptoms and informed them about his vaccines. As soon as a hospitalist saw him and diagnosed
Michelle56pr
in
Prostate Cancer Network
3 years ago
Lutetium-617 vs Lutetium-TLX591 plus Xyandi after Zytiga failure. Question from Australia.
Hi from Australia Congrats on FDA approval for Lutetium! I’m looking for any information about lutetium TLX591 which is being used in prostACT clinical trial here. Considering joining this trial vs lutetium 617 (used in VISION trial and the mainstay of lutetium therapy for quite some time here, Germany
Hi from Australia Congrats on FDA approval for Lutetium! I’m looking for any information about lutetium TLX591 which is being used in prostACT clinical trial here. Considering joining this trial vs lutetium 617 (used in VISION trial and the mainstay of lutetium therapy for quite some time here, Germany
MarkEmrys
in
Advanced Prostate Cancer
3 years ago
1
...
63
64
65
...
100
Next page
20
30
40
50
60
70
80
90
100
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
1326 results
Cure Parkinson's
664 results
CLL Support
633 results
View top 10 communities
Sort by
Most Relevant
Newest